Henry Schein, Inc. (NASDAQ:HSIC) Receives Consensus Recommendation of "Hold" from Analysts

Henry Schein, Inc. (NASDAQ:HSIC - Get Free Report) has been given a consensus rating of "Hold" by the eleven analysts that are covering the stock, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, five have issued a hold recommendation and five have given a buy recommendation to the company. The average 12-month price objective among brokerages that have issued ratings on the stock in the last year is $81.09.

HSIC has been the subject of several recent research reports. Leerink Partnrs reiterated a "market perform" rating on shares of Henry Schein in a research report on Monday, February 26th. JPMorgan Chase & Co. lifted their price target on Henry Schein from $82.00 to $88.00 and gave the company an "overweight" rating in a research report on Wednesday, March 6th. Jefferies Financial Group boosted their price objective on Henry Schein from $74.00 to $81.00 and gave the company a "hold" rating in a research report on Wednesday, March 6th. TheStreet upgraded Henry Schein from a "c+" rating to a "b-" rating in a research report on Monday, February 26th. Finally, SVB Leerink started coverage on Henry Schein in a research report on Monday, February 26th. They issued a "market perform" rating and a $78.00 price objective for the company.

Henry Schein Stock Performance

Shares of Henry Schein stock traded down $0.05 on Thursday, reaching $71.81. 828,831 shares of the stock were exchanged, compared to its average volume of 1,119,810. The company has a quick ratio of 1.00, a current ratio of 1.67 and a debt-to-equity ratio of 0.45. Henry Schein has a twelve month low of $60.01 and a twelve month high of $85.65. The firm has a market capitalization of $9.23 billion, a price-to-earnings ratio of 22.80, a PEG ratio of 1.80 and a beta of 0.87. The business has a 50 day moving average price of $74.91 and a two-hundred day moving average price of $72.60.

Henry Schein (NASDAQ:HSIC - Get Free Report) last released its earnings results on Tuesday, February 27th. The company reported $0.66 EPS for the quarter, missing analysts' consensus estimates of $0.70 by ($0.04). Henry Schein had a return on equity of 14.03% and a net margin of 3.37%. The firm had revenue of $3.02 billion for the quarter, compared to analyst estimates of $3 billion. During the same period last year, the firm earned $1.21 EPS. The company's revenue for the quarter was down 10.5% compared to the same quarter last year. Analysts anticipate that Henry Schein will post 5.07 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Henry Schein news, Vice Chairman James P. Breslawski sold 2,907 shares of the business's stock in a transaction on Monday, March 18th. The stock was sold at an average price of $74.37, for a total transaction of $216,193.59. Following the transaction, the insider now owns 209,562 shares of the company's stock, valued at $15,585,125.94. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. In other news, CEO Bradford C. Connett sold 6,430 shares of the company's stock in a transaction on Wednesday, March 20th. The stock was sold at an average price of $74.28, for a total value of $477,620.40. Following the transaction, the chief executive officer now owns 73,108 shares of the company's stock, valued at approximately $5,430,462.24. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Vice Chairman James P. Breslawski sold 2,907 shares of the company's stock in a transaction on Monday, March 18th. The shares were sold at an average price of $74.37, for a total value of $216,193.59. Following the completion of the transaction, the insider now directly owns 209,562 shares in the company, valued at approximately $15,585,125.94. The disclosure for this sale can be found here. 1.14% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Henry Schein

Several institutional investors and hedge funds have recently modified their holdings of the company. Cambridge Investment Research Advisors Inc. raised its holdings in shares of Henry Schein by 2.4% in the 1st quarter. Cambridge Investment Research Advisors Inc. now owns 5,262 shares of the company's stock valued at $459,000 after buying an additional 122 shares during the period. Aurora Investment Counsel raised its holdings in shares of Henry Schein by 0.7% in the 3rd quarter. Aurora Investment Counsel now owns 20,641 shares of the company's stock valued at $1,533,000 after buying an additional 140 shares during the period. Arizona State Retirement System raised its holdings in shares of Henry Schein by 0.4% in the 4th quarter. Arizona State Retirement System now owns 35,890 shares of the company's stock valued at $2,717,000 after buying an additional 149 shares during the period. Studio Investment Management LLC raised its holdings in shares of Henry Schein by 3.9% in the 4th quarter. Studio Investment Management LLC now owns 4,160 shares of the company's stock valued at $332,000 after buying an additional 155 shares during the period. Finally, Kentucky Retirement Systems Insurance Trust Fund raised its holdings in shares of Henry Schein by 3.4% in the 3rd quarter. Kentucky Retirement Systems Insurance Trust Fund now owns 4,878 shares of the company's stock valued at $321,000 after buying an additional 161 shares during the period. Hedge funds and other institutional investors own 96.62% of the company's stock.

About Henry Schein

Henry Schein, Inc provides health care products and services to dental practitioners and laboratories, physician practices, ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.